iSpecimen Inc.

NasdaqCM ISPC

iSpecimen Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -93.92%

iSpecimen Inc. Operating Income Margin is -93.92% for the Trailing 12 Months (TTM) ending September 30, 2024, a 7.21% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.
  • iSpecimen Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -101.22%, a -0.71% change year over year.
  • iSpecimen Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -100.50%, a -133.52% change year over year.
  • iSpecimen Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -43.04%, a -32.73% change year over year.
  • iSpecimen Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -32.42%.
Key data
Date Operating Income Margin EBT Margin Net Income Margin EBITDA Margin
Market news
Loading...
SV Wall Street
NasdaqCM: ISPC

iSpecimen Inc.

CEO Mr. Robert Bradley Lim
IPO Date June 17, 2021
Location United States
Headquarters 450 Bedford Street
Employees 53
Sector Health Care
Industries
Description

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Similar companies

XGN

Exagen Inc.

USD 5.27

-1.13%

PSNL

Personalis, Inc.

USD 5.16

-3.19%

FONR

FONAR Corporation

USD 16.02

-1.11%

CSTL

Castle Biosciences, Inc.

USD 27.83

-1.03%

OCX

OncoCyte Corporation

USD 2.05

-5.09%

INBS

Intelligent Bio Solutions Inc.

USD 1.95

14.71%

StockViz Staff

February 8, 2025

Any question? Send us an email